Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: Involvement of the Ras/ERK/PLTP pathway

Journal of Cellular Physiology

Volumn 227, Issue 9, 2012, Pages 3185-3191

  Guo, Ling Li ^a   Chen, Ya Juan ^a,b   Wang, Tao ^a   An, Jing ^a   Wang, Cheng Na ^a   Shen, Yong Chun ^a   Yang, Ting ^a   Zhao, Li ^a   Zuo, Qiu Nan ^a   Zhang, Xiao Hong ^a   Xu, Dan ^a   Wen, Fu Qiang ^a  

^a SICHUAN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; MITOGEN ACTIVATED PROTEIN KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; RAS PROTEIN; SIMVASTATIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL LINE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENES, RAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, LDL; MAP KINASE KINASE KINASE 3; MAP KINASE SIGNALING SYSTEM; MEVALONIC ACID; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHORYLATION; PULMONARY ALVEOLI; RESPIRATORY DISTRESS SYNDROME, ADULT; RNA, SMALL INTERFERING; SIMVASTATIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84862101929     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24005     Document Type: Article

References (39)

1. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA, Lemaire F, Long W, Zaccardelli DS, Pattishall EN. 1996. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 334: 1417-1421.
2. Beers MF, Solarin KO, Guttentag SH, Rosenbloom J, Kormilli A, Gonzales LW, Ballard PL. 1998. TGF-β1 inhibits surfactant component expression and epithelial cell maturation in cultured human fetal lung. Am J Physiol Lung Cell Mol Physiol 275: L950-L960.
3. Chandel NS, Budinger GRS, Mutlu GM, Varga J, Synenki L, Donnelly HK, Zirk A, Eisenbart J, Jovanovic B, Jain M. 2009. Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways* Crit Care Med 37: 1678-1684.
4. Clavreul N, Bachschmid MM, Hou X, Shi C, Idrizovic A, Ido Y, Pimental D, Cohen RA. 2006. S-glutathiolation of p21ras by peroxynitrite mediates endothelial insulin resistance caused by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 26: 2454-2461.
5. Cuschieri J, Gourlay D, Garcia I, Jelacic S, Maier RV. 2002. Hypertonic preconditioning inhibits macrophage responsiveness to endotoxin. J Immunol 168: 1389-1396.
6. Davidson BA, Knight PR, Wang Z, Chess PR, Holm BA, Russo TA, Hutson A, Notter RH. 2005. Surfactant alterations in acute inflammatory lung injury from aspiration of acid and gastric particulates. Am J Physiol Lung Cell Mol Physiol 288: L699-L708.
7. Deigner HP, Claus R. 1996. Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells. FEBS Lett 385: 149-153.
8. Frank J, Roux J, Kawakatsu H, Su G, Dagenais A, Berthiaume Y, Howard M, Canessa CM, Fang X, Sheppard D. 2003. Transforming growth factor-β1 decreases expression of the epithelial sodium channel αENaC and alveolar epithelial vectorial sodium and fluid transport via an ERK1/2-dependent mechanism. J Biol Chem 278: 43939-43950.
9. Gregory T, Longmore W, Moxley M, Whitsett J, Reed C, Fowler AA. 1991. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 88: 1976-1981.
10. Hall SB, Notter RH, Smith RJ, Hyde RW. 1990. Altered function of pulmonary surfactant in fatty acid lung injury. J Appl Physiol 69: 1143-1149.
11. Hong HK, Song CY, Kim BC, Lee HS. 2006. ERK contributes to the effects of Smad signaling on oxidized LDL-induced PAI-1 expression in human mesangial cells. Trans Res 148: 171-179.
12. Huang W, McCaig L, Veldhuizen R, Yao L, Lewis J. 2005. Mechanisms responsible for surfactant changes in sepsis-induced lung injury. Eur Respir J 26: 1074-1079.
13. Javelaud D, Mauviel A. 2005. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-β: Implications for carcinogenesis. Oncogene 24: 5742-5750.
14. Jiang X, D'Armiento J, Mallampalli RK, Mar J, Yan SF, Lin M. 1998. Expression of plasma phospholipid transfer protein mRNA in normal and emphysematous lungs and regulation by hypoxia. J Biol Chem 273: 15714-15718.
15. Jobe AH. 1993. Pulmonary surfactant therapy. N Engl J Med 328: 861-868.
16. Kamanna VS, Bassa BV, Vaziri ND, Roh DD. 1999. Atherogenic lipoproteins and tyrosine kinase mitogenic signaling in mesangial cells. Kidney Int 56: S70-S75.
17. Kaushal S, Ghosh S, Sharma N, Sanyal S, Majumdar S. 2001. Role of phospholipid transfer protein in rabbit lung development. Cell Mol Life Sci 58: 2098-2107.
18. Kuzmenko A, Wu H, Bridges J, McCormack F. 2004. Surfactant lipid peroxidation damages surfactant protein A and inhibits interactions with phospholipid vesicles. J Lipid Res 45: 1061-1068.
19. Lan Y, Zhou Q, Wu ZL. 2004. NF-kappa B involved in transcription enhancement of TGF-beta 1 induced by Ox-LDL in rat mesangial cells. Chinese Med J 117: 225-230.
20. Li C, Zhu NL, Tan RC, Ballard PL, Derynck R, Minoo P. 2002. Transforming growth factor-β inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2. 1 and HNF-3 transcription factors. J Biol Chem 277: 38399-38408.
21. Marampon F, Bossi G, Ciccarelli C, Di Rocco A, Sacchi A, Pestell RG, Zani BM. 2009. MEK/ERK inhibitor U0126 affects in vitro and in vivo growth of embryonal rhabdomyosarcoma. Mol Cancer Ther 8: 543-551.
22. Mazière C, Mazière JC. 2009.
23. Miura S, Matsuo Y, Saku K. 2004. Simvastatin suppresses coronary artery endothelial tube formation by disrupting Ras/Raf/ERK signaling. Atherosclerosis 175: 235-243.
24. Perez-Gil J, Weaver TE. 2010. Pulmonary surfactant pathophysiology: Current models and open questions. Physiology 25: 132-141.
25. Pittet JF, Griffiths MJD, Geiser T, Kaminski N, Dalton SL, Huang X, Brown LAS, Gotwals PJ, Koteliansky VE, Matthay MA. 2001. TGF-beta is a critical mediator of acute lung injury. J Clin Invest 107: 1537-1562.
26. Russo TA, Wang Z, Davidson BA, Genagon SA, Beanan JM, Olson R, Holm BA, Knight PR, Chess PR, Notter RH. 2007. Surfactant dysfunction and lung injury due to the E. coli virulence factor hemolysin in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol 292: L632-L643.
27. Sipahi EY, Ozel Tekin I, Comert M, Barut F, Ustun H, Sipahi TH. 2004. Oxidized low-density lipoproteins accumulate in rat lung after experimental lung edema induced by alpha-naphthylthiourea (ANTU). Pharmacol Res 50: 585-591.
28. Song CY, Kim BC, Hong HK, Lee HS. 2005. Oxidized LDL activates PAI-1 transcription through autocrine activation of TGF-β signaling in mesangial cells. Kidney Int 67: 1743-1752.
29. Song CY, Kim BC, Lee HS. 2008. Lovastatin inhibits oxidized low-density lipoprotein-induced plasminogen activator inhibitor and transforming growth factor-[beta] 1 expression via a decrease in Ras/extracellular signal-regulated kinase activity in mesangial cells. Trans Res 151: 27-35.
30. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF, Witte MC, Richards GA, Rippin G, Rathgeb F. 2004. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 351: 884-892.
31. Tapiero H, Townsend DM, Tew KD. 2004. Organosulfur compounds from alliaceae in the prevention of human pathologies. Biomed Pharmacother 58: 183-193.
32. Tascilar O, Cakmak GK, Tekin IO, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Irkorucu O, Karakaya K, Balbaloglu H. 2007. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 13: 6172-6182.
33. Tu AY, Cheung MC, Zhu X, Knopp RH, Albers JJ. 2004. Low-density lipoprotein inhibits secretion of phospholipid transfer protein in human trophoblastic BeWo cells. Exp Biol Med 229: 1046-1052.
34. Vuletic S, Dong W, Wolfbauer G, Day JR, Albers JJ. 2009. PLTP is present in the nucleus, and its nuclear export is CRM1-dependent. Biochim Biophys Acta Mol Cell Res 1793: 584-591.
35. Wesselkamper SC, Case LM, Henning LN, Borchers MT, Tichelaar JW, Mason JM, Dragin N, Medvedovic M, Sartor MA, Tomlinson CR. 2005. Gene expression changes during the development of acute lung injury role of transforming growth factor {beta}. Am J Respir Crit Care Med 172: 1399-13411.
36. Yue J, Mulder KM. 2000a. Activation of the mitogen-activated protein kinase pathway by transforming growth factor-beta. Methods Mol Biol 142: 125-132.
37. Yue J, Mulder KM. 2000b. Requirement of Ras/MAPK pathway activation by transforming growth factor-β for transforming growth factor-β1production in a SMAD-dependent pathway. J Biol Chem 275: 30765-30773.
38. Zeki AA, Franzi L, Last J, Kenyon NJ. 2009. Simvastatin inhibits airway hyperreactivity: Implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180: 731-740.
39. Zhou J, Ryan AJ, Medh J, Mallampalli RK. 2003. Oxidized lipoproteins inhibit surfactant phosphatidylcholine synthesis via calpain-mediated cleavage of CTP: Phosphocholine cytidylyltransferase. J Biol Chem 278: 37032-37040.